Beximco Pharmaceuticals Limited

LSE:BXP.LHealthcare

——At close · Market cap —

BXP.L · Income statement · TradingHolo

BDT billions	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	YoY
Revenue	22.8	25.6	29.5	34.7	39.3	44.4	+13.1%
Cost of revenue	12.2	13.7	15.6	18.9	22.2	24.8	+11.7%
Gross profit	10.6	11.9	13.9	15.8	17.1	19.6	+14.8%
Research & development	0.0	0.2	0.2	0.3	0.4	0.0	−99.2%
Selling, general & administrative	5.6	6.3	7.3	8.9	5.2	5.6	+6.6%
Selling & marketing	4.8	5.5	6.4	7.7	4.6	4.9	+6.7%
Operating expenses	5.8	6.5	7.2	8.9	9.9	11.0	+10.7%
Operating income	5.1	5.6	6.7	6.9	7.2	8.7	+20.2%
Interest expense	1.0	1.0	0.9	1.0	1.3	1.2	−9.8%
Interest income	0.0	0.0	0.0	0.0	0.0	0.0	+185.2%
Other income / expense	(1.1)	(1.0)	(0.3)	(0.2)	(1.1)	(1.1)	−0.1%
Pre-tax income	3.9	4.7	6.4	6.7	6.1	7.5	+24.0%
Income tax	0.9	1.1	1.2	1.7	1.5	1.7	+7.4%
Net income	3.0	3.5	5.1	5.1	4.6	5.8	+26.3%
Discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	—
Other net income adjustments	0.0	0.0	0.0	0.0	0.0	0.0	—
EPS, basic (per share)	6.80	7.88	11.49	11.48	10.34	13.07	+26.4%
EPS, diluted (per share)	6.80	7.88	11.49	11.48	10.34	13.07	+26.4%
EBITDA	5.1	5.8	7.4	8.2	9.4	10.6	+13.5%
Depreciation & amortization	0.2	0.2	0.2	1.7	2.1	2.0	−3.2%
Weighted average shares (shares)	446,112,089	445,923,417	446,112,089	446,112,089	446,112,000	446,112,000	+0.0%
Weighted average diluted shares (shares)	446,112,089	445,923,417	446,112,089	446,112,089	446,112,000	446,112,000	+0.0%
Gross margin	46.5%	46.5%	47.2%	45.6%	43.6%	44.2%	+0.7 pts
Operating margin	22.2%	21.9%	22.5%	19.9%	18.4%	19.5%	+1.2 pts
Net margin	13.3%	13.7%	17.4%	14.8%	11.8%	13.1%	+1.4 pts

BDT billionsUpdated 30 Sep 2025 ·

ⓘ

Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.

Statements are reported in BDT; the shares trade in GBP.